Advances in Alzheimer's and Parkinson's Disease

Clinical Features and Treatment of Dementia Associated With Parkinson’s Disease.- Neurogenetics in Parkinson's Disease.- Impaired DNA Repair Systems: Generation of Mitochondrial Dysfunction and Increased Sensitivity to Excitotoxicity.- Current Problems and Strategies in Motor Rehabilitation for Parkinson’s Disease.- Critical Acute Akinesia in Parkinson’s Disease Patients Concomitant with Additional Precipitating Factors Other Than Treatment Withdrawal: A Possible Lethal Complication.- Biomarkers for Early Detection of Parkinson’s Disease: An Essential Challenge.- Neurotransmitter and Neurotrophic Factor-Secreting Cell Line Grafting for the Treatment of Parkinson’s Disease.- Novel Therapeutic Target in PD: Experimental Models.- LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism.- Microglia Activation and Gene Expression of Cytokines in Parkinson’s Disease.- Dissecting the Biochemical Pathways Mediated by Genes Implicated in Parkinson’s Disease: Induction of DJ-1 Expression in A30P ?-Synuclein Mice.- Neuroinflammation in Early Stages of Alzheimer’s Disease and Parkinson’s Disease.- Alzheimer’s Disease, Parkinson’s Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding.- Role of Oxidative Insult and Neuronal Survival in Alzheimer’s and Parkinson’s Diseases.- Redox Proteomics Identification of Oxidatively Modified Proteins in Alzheimer’s Disease Brain and in Brain from a Rodent Model of Familial Parkinson’s Disease: Insights into Potential Mechanisms of Neurodegeneration.- Biomarkers for Alzheimer’s Disease and Parkinson’s Disease.- Bioluminescent Imaging of Excitotoxic and Endotoxic Brain Injury in Living Mice.- Alzheimer’s Disease Neuroimaging Initiative.- Two Hits andYou’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease.- Vascular Risk Factors and Risk for Alzheimer’s Disease and Mild Cognitive Impairment: Population-Based Studies.- Cholesterol Transport and Production in Alzheimer’s Disease.- Cholesterol and A? Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis.- Glycosaminoglycans and Analogs in Neurodegenerative Disorders.- Prospective Role of Glycosaminoglycans in Apoptosis Associated with Neurodegenerative Disorders.- Stem Cell Therapy in Alzheimer’s Disease.- Oral A? Vaccine Using a Recombinant Adeno-Associated Virus Vector in an Alzheimer’s Disease Mouse Model.- In Vivo Targeting of Amyloid Plaques Via Intranasal Administration of Phage Anti-?-Amyloid Antibodies.- Decreased ProBDNF: The Cause of Alzheimer’s-Associated Neurodegeneration and Cognitive Decline?.- Shift in the Balance of TRKA and ProNGF in Prodromal Alzheimer ’s Disease.- Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Intracellular Kinases.- Intraneuronal A? and Alzheimer’s Disease.- Physiological Processing of the Cellular Prion Protein and ?APP: Enzymes and Regulation.- Expression of Wnt Receptors, Frizzled, in Rat Neuronal Cells.- Cell Models of Tauopathy.- Co-expression of FTDP-17 Human Tau and GSK-3ß (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration.- Enhanced Activation of NF-?B Signaling by Apolipoprotein E4.- Pleiotropic Effects of Apolipoprotein E in Dementia: Influence on Functional Genomics and Pharmacogenetics.- Up-regulation of the ?-Secretase Pathway.- Frequency and Relation of Argyrophilic Grain Disease and Thorn-Shaped Astrocytes in Alzheimer’s Disease.- Cellular Membranes as Targets in Amyloid Oligomer DiseasePathogenesis.- Ganglioside-Dependent Generation of a Seed for Alzheimer’s Disease Amyloid.- Evidence That Amyloid Pathology Progresses in a Neurotransmitter-Specific Manner.- Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimer’s Disease.- Cortical Cholinergic Lesion Causes A? Deposition: Cholinergic-Amyloid Fusion Hypothesis.- Expression of Acetylcholinesterase in Alzheimer’s Disease Brain: Role in Neuritic Dystrophy and Synaptic Scaling.- Role of b-Amyloid in the Pathophysiology of Alzheimer’s Disease and Cholinesterase Inhibition: Facing the Biological Complexity to Treat the Disease.- Dissociation Between the Potent ?-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine.- Allosteric Potentiators of Neuronal Nicotinic Cholinergic Receptors: Potential Treatments for Neurodegenerative Disorders.